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ABSTRACT
Background: To estimate the efficacy and safety of 0.1% tacrolimus ophthalmic suspension based on the
blood level of tacrolimus in patients with severe allergic conjunctivitis.
Methods: Fifty-two patients in whom topical anti-allergic agents had been ineffective were treated with 0.1%
tacrolimus ophthalmic suspension twice daily for 12 weeks. Adverse drug reactions were monitored, as well as
ocular symptoms and signs. The blood concentration of tacrolimus was measured before the initiation of treat-
ment and 4 and 12 weeks later.
Results: About 75% of the patients without concomitant using of tacrolimus ointment had blood levels of
tacrolimus below the detection limit of the assay (0.5 ngmL). On the other hand, 71% (week 4) and 57% (week
12) of patients with concomitant using of tacrolimus ointment had blood levels above the detection limit of the
assay. However, the maximum blood concentration was less than 2 ngmL. Adverse drug reactions occurred in
16 patients. These were disorders of the eye such as warmness, irritation, and a burning sensation. However,
all of the patients could continue treatment with tacrolimus for 12 weeks. There were no serious adverse events
such as increased intraocular pressure or ocular infection during the study. All symptoms and signs improved
over time.
Conclusions: The good safety profile of 0.1% tacrolimus ophthalmic suspension based on the low blood con-
centration of tacrolimus, coupled with demonstrated efficacy, make it an important tool for treating severe aller-
gic conjunctivitis.
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INTRODUCTION
Topical anti-allergy agents and steroids are the first-
line treatments for severe allergic conjunctivitis, such
as vernal keratoconjunctivitis (VKC) or atopic kerato-
conjunctivitis (AKC). However, these diseases re-
quire long-term treatment in many cases, and ster-
oids cannot be administered because long-term ster-
oid therapy often results in significant adverse reac-
tions such as increased intraocular pressure,1 espe-
cially in children under the age of 10 years,2 as well
as infections.3 It is also true, however, that there are
few effective treatment options for severe allergic
conjunctivitis that provide as an alternative to topical
steroids.4
Tacrolimus is a macrolide antibiotic produced by
Streptomyces tsukubaensis.5 Due to its potent immuno-
suppressive effect, oral and parenteral tacrolimus
preparations were developed for preventing rejection
after organ transplantation. Subsequently, tacrolimus
ointment was released for atopic dermatitis and auto-
immune skin diseases, and it is now available all over
the world. In recent years, there have been several
reports about the usefulness of cyclosporin ophthal-
mic solution and tacrolimus ointment for the treat-
ment of VKC and AKC.6-10 Both of these drugs are
calcineurin inhibitors that block the activation of T
cells and their production of cytokines involved in the
development of VKC and AKC. Based on the fact that
the inhibitory effect of tacrolimus on cytokine produc-
tion by T cells is about 100 times greater than that of
cyclosporin,11 an ophthalmic tacrolimus preparation
is expected to be effective for severe VKC and AKC.
Previously, we examined the efficacy of a 0.1%
tacrolimus ophthalmic suspension (TALYMUS®,
Senju Pharmaceutical Co., Ltd., Osaka, Japan) for se-
vere allergic conjunctivitis in a multicenter, random-
ized, double-blinded, placebo-controlled clinical
trial.12 Fifty-six patients were treated either with
tacrolimus or placebo twice daily for 4 weeks. As a re-
sult, both objective findings and subjective symptoms
were significantly better in the tacrolimus group than
in the placebo group.
Although tacrolimus is a very useful immunosup-
pressant, it is known from previous experience with
oral preparations that a persistently high blood con-
centration of the drug (trough level10-20 ngmL) is
associated with renal impairment.13 On the other
hand, after topical application of tacrolimus ointment
for treatment of atopic dermatitis, the blood concen-
tration is usually low or undetectable.14 However, Rita
L et al. recently reported that there may be an in-
creased risk of T cell lymphoma in atopic dermatitis
patients treated with tacrolimus ointment.15 The theo-
retical risk of cancer from exposure is low because no
evidence of systemic accumulation has been ob-
served after repeated application of tacrolimus oint-
ment. However, younger patients with a higher body
surface area per weight and subjects with abnormali-
ties of the epidermis can display considerable percu-
taneous absorption of tacrolimus ointment that may
result in blood concentrations corresponding to the
levels known to cause immunosuppression. The risk
of severe systemic reactions to tacrolimus may de-
pend on its blood level. Therefore, this study was
conducted to clarify the blood level of tacrolimus after
ocular instillation of a 0.1% ophthalmic suspension in
patients with severe allergic conjunctivitis and to ex-
amine adverse drug reactions.
METHODS
This multicentre, prospective, open-label, non-compa-
rative clinical study of patients with severe allergic
conjunctivitis (VKC and AKC) was conducted at 11
institutions. We diagnosed VKC patients for charac-
teristic appearances such as giant papillae in upper
tarsal conjunctivae, Trantas dot in limbal conjuncti-
vae. A various corneal disorders such as superficial
punctate keratitis, shield ulcer and corneal plaque
were observed in corneas of VKC patients. 15 VKC
patients were enrolled in this study. On the other
hand, chronic AKC patients had fibrosis of upper tar-
sal conjunctivae and neovascularization of corneas.
However, acute AKC patients had severe papillae in
upper tarsal conjunctivae and various corneal disor-
ders. In this study, among AKC patients, we chose
patients with severe papillae in upper tarsal conjuncti-
vae. 37 AKC patients were enrolled in this study. The
study was performed from May 2008 to September
2009 and its protocol was approved by the Institu-
tional Review Boards of all participating institutions.
In addition, the study was carried out in accordance
with the Declaration of Helsinki, Good Clinical Prac-
tice, and Good Post-marketing Study Practice (Ja-
pan). All patients who participated in this study gave
written consent after the details had been explained
to them. The study was registered with the Japanese
University Hospital Medical Information Network
(https:center.umin.ac.jp) and was assigned the ID
code UMIN000001262.
Patients who had been diagnosed as having severe
allergic conjunctivitis and for whom topical anti-
allergic agents were ineffective were eligible for this
study. The following patients were excluded from the
study: (1) those who had known hypersensitivity to
tacrolimus hydrate or to any component of this drug;
(2) those with infectious eye diseases; (3) women
who were pregnant or possibly pregnant; (4) patients
who had already used an ophthalmic preparation of
tacrolimus hydrate (including in clinical trials); (5)
patients using tacrolimus capsules, granules andor
injections; (6) patients who wore contact lenses; and
(7) patients who had participated in any other clinical
trial within 3 months prior to enrollment.
Patients were instructed to instill one drop of 0.1%
tacrolimus ophthalmic suspension into both eyes
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Table　1　Baseline characteristics of the patients
AKC
(n = 37)
VKC
(n = 15)
Age (yrs): mean ± SD (range) 17.4 ± 11.02 14.1 ± 8.4
(5-41) (6-36)
Sex Male (%) 30 (81.1%) 12 (80.0%)
Female  7 3
Concomitant medications:
Topical steroids 18 6
Oral steroids  3 0
Tacrolimus ointment  7 0
Total symptom score 6.9 ± 4.44  5.9 ± 3.35
Total clinical sign score 15.6 ± 4.8 16.4 ± 4.97
AKC, Atopic keratoconjunctivitis; VKC, Vernal keratoconjunctivitis.
twice a day for 12 weeks. Patient’s compliances with
the administration of the drug were confirmed at
each observational time point during the study. Al-
most patients were in compliance with the rule of pre-
scriptions in this study. Concomitant administration
of tacrolimus ointment for severe atopic dermatitis
was allowed without any dose change from 4 weeks
prior to and during the study.
Safety was assessed from ocular findings, visual
acuity, intraocular pressure, adverse events, and labo-
ratory test results. All adverse events observed by the
investigators or reported by patients in weeks 2, 4, 8,
and 12 were recorded. Each event was graded as
mild, moderate, or severe, and the potential relation-
ship to the study drug was assessed. For laboratory
tests, blood samples were obtained from a cubital
vein in weeks 4 and 12.
To evaluate systemic absorption after topical instil-
lation of 0.1% tacrolimus ophthalmic suspension, ap-
proximately 1 mL of whole venous blood was col-
lected before the initiation of administration and after
4 and 12 weeks of treatment. We collected blood sam-
ples at three-four hours after the last administration
of tacrolimus suspension. The blood concentration of
tacrolimus was measured by using liquid chromatog-
raphy tandem mass spectrometry (LC-MS2) at the
Osaka laboratory of JCL Bioassay Corp. (Osaka, Ja-
pan). LC-MS2 is widely used for quantitative determi-
nation of immunosuppressive drugs in biological flu-
ids, because of the features such as selectivity and
lower cost of analysis.16
Ten ocular findings were assessed, including 5 for
the tarsal conjunctiva (hyperemia, swelling, follicles,
papillae, and giant papillae), 2 for the bulbar conjunc-
tiva (hyperemia and edema), and limbal edema, Tran-
tas’ dots, and corneal lesions. Six ocular symptoms
were also assessed, including itching, eye discharge,
lacrimation, eye pain, foreign body sensation, and
photophobia. Each of these signssymptoms was
graded on a 4-point scale (0 = none, 1 = mild, 2 = mod-
erate, or 3 = severe). The primary efficacy outcome
measure was the mean change of the total score for
the 10 ocular findings.
Statistical analysis was performed using JMP statis-
tical software (version 8 for Windows, SAS Institute
Inc., Cary, NC, USA). Significance was accepted at a
two-sided level of P < 0.05. Efficacy assessments were
based on the worse eye (the eye with a higher total
score for ocular findings), with the total scores being
compared between baseline and post-treatment by
the Wilcoxon signed rank test.
RESULTS
PATIENT PROFILE
The baseline characteristics and clinical scores of the
subjects are shown in Table 1. A total of 52 patients
(42 males and 10 females) were enrolled. The mean
age was 17.4 years for those with AKC and 14.1 years
for those with VKC. In 18 of the 37 AKC patients and
6 of the 15 VKC patients, corticosteroid eye drops
andor ointment were being used at study initiation.
However, only 5 patients with AKC were still using
steroids at the completion of the study. Tacrolimus
ointment was used by 7 patients for treatment of se-
vere atopic dermatitis.
BLOOD LEVEL OF TACROLIMUS
Table 2A, B show the blood levels of tacrolimus in
various subsets of patients without or with concomi-
tant using of tacrolimus ointment at all the three
points (Initialweek4 and week12). About 75% of the
patients without concomitant using of tacrolimus oint-
ment had blood levels below the detection limit of the
assay (0.5 ngmL). In the other hand, 71% (week 4)
and 57% (week12) of patients with concomitant using
of tacrolimus ointment had blood levels above the de-
tection limit of the assay (0.5 ngml). However, the
maximum blood concentrations of both groups were
always less than 2 ngmL. In the others, the mean
blood level was not affected by sex, age, steroid ther-
Ebihara N et al.
278 Allergology International Vol 61, No2, 2012 www.jsaweb.jp
Table　2A　Systemic exposure to tacrolimus without concomitant using of tacrolimus ointment
Blood level of tacrolimus (ng/mL)
Time Point
P value*
Initial Week4 Week12
Sex Male Mean ± SD N.D. 0.27 ± 0.462 0.3 ± 0.498
0.0832
Max ― 1.47 1.78
N† (0/36) (10/34) (12/36)
Female Mean ± SD N.D. N.D. N.D.
Max ― ― ―
N† (0/9) (0/9) (0/8)
Age <10 Mean ± SD N.D. 0.15 ± 0.295 0.16 ± 0.263
0.1622
Max ― 0.82 0.59
N† (0/14) (3/14) (4/14)
10-15 Mean ± SD N.D. 0.13 ± 0.385 0.15 ± 0.455
Max ― 1.47 1.78
N† (0/18) (2/16) (2/17)
>15 Mean ± SD N.D. 0.39 ± 0.549 0.47 ± 0.587
Max ― 1.43 1.64
N† (0/13) (5/13) (6/13)
Steroid therapy Yes Mean ± SD N.D. 0.18 ± 0.427 0.20 ± 0.442
0.4887
Max ― 1.43 1.64
N† (0/25) (4/24) (5/24)
No Mean ± SD N.D. 0.26 ± 0.427 0.31 ± 0.494
Max ― 1.47 1.78
N† (0/20) (6/19) (7/20)
Severity 
(corneal involvement)
Mild Mean ± SD N.D. 0.33 ± 0.586 0.35 ± 0.655
0.4391
Max ― 1.47 1.78
N† (0/15) (4/15) (4/15)
Moderate Mean ± SD N.D. 0.17 ± 0.312 0.26 ± 0.379
Max ― 0.91 1.09
N† (0/17) (4/16) (6/17)
Severe Mean ± SD N.D. 0.13 ± 0.299 0.09 ± 0.211
Max ― 0.82 0.57
N† (0/13) (2/12) (2/12)
†No. of detected/total patients.
*P value were calculated with the use of MANOVA test.
apy and severity.
SAFETY
Adverse drug reactions were reported in 16 patients.
The incidence of adverse drug reactions among the
20 patients who had detectable blood levels of
tacrolimus was 30.0%, which was very close to the
31.3% for patients without detectable levels (below
the lower limit of quantification). All of the adverse
drug reactions are listed in Table 3. No serious ad-
verse events or ocular infections occurred during the
treatment with the study drug. Although laboratory
abnormalities occurred in 8 cases, no clinically rele-
vant problems were observed.
The changes from baseline of visual acuity and in-
traocular pressure after 12 weeks are shown in Table
4. Baseline of visual acuities of patients was im-
proved. As for the mean intraocular pressure, eleva-
tion was not recognized in patients with or without
concomitant steroid use.
EFFICACY
At the start of treatment, the mean symptom score
was 7.7 ± 4.46 in the steroid group and 5.5 ± 3.54 in
the non-steroid group. These scores showed a signifi-
cant decrease to 2.5 ± 3.01 (P < 0.001) and 2.0 ± 2.04
(P < 0.001), respectively, in week 2 (Fig. 1). The
scores decreased further to 1.2 ± 1.93 for the steroid
group and 0.9 ± 1.42 for the non-steroid group by
week 12. As for ocular findings, the mean score at the
start of treatment was 16.0 ± 5.26 for the steroid
group and 15.8 ± 4.42 for the non-steroid group.
These scores decreased significantly to 10.8 ± 4.66 (P
< 0.001) and 9.9 ± 3.36 (P < 0.001), respectively, in
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Table　2B　Systemic exposure to tacrolimus with concomitant using of tacrolimus ointment
Blood level of tacrolimus (ng/mL)
Time Point
P value*
Initial Week4 Week12
Sex Male Mean ± SD N.D. 0.75 ± 0.754 0.79 ± 0.758
0.5599
Max ― 1.69 1.83
N† (0/6) (4/6) (4/6)
Female Mean ± SD N.D. 0.64 N.D.
Max ― 0.64 ―
N† (0/1) (1/1) (0/1)
Age <10 Mean ± SD N.D. 0.52 ± 0.485 0.28 ± 0.479
0.3049
Max ― 0.96 0.83
N† (0/3) (2/3) (1/3)
10-15 Mean ± SD ― ― ―
Max ― ― ―
N† (0) (0) (0)
>15 Mean ± SD N.D. 0.90 ± 0.737 0.98 ± 0.836
Max ― 1.69 1.83
N† (0/4) (3/4) (3/4)
Steroid therapy Yes Mean ± SD N.D. 1.26 1.50
0.2921
Max ― 1.26 1.50
N† (0/1) (1/1) (1/1)
No Mean ± SD N.D. 0.65 ± 0.636 0.54 ± 0.725
Max ― 1.69 1.83
N† (0/6) (4/6) (3/6)
Severity
 (corneal involvement)
Mild Mean ± SD N.D. 0.64 N.D.
0.8503
Max ― 0.64 ―
N† (0/1) (1/1) (0/1)
Moderate Mean ± SD N.D. 0.81 ± 0.706 0.67 ± 0.870
Max ― 1.69 1.83
N† (0/4) (3/4) (2/4)
Severe Mean ± SD N.D. 0.63 ± 0.891 1.05 ± 0.636
Max ― 1.26 1.50
N† (0/2) (1/2) (2/2)
†No. of detected / total patients.
*P value were calculated with the use of MANOVA test.
week 2, and then decreased further to 6.5 ± 3.44 and
4.5 ± 3.15, respectively, by week 12.
DISCUSSION
The 0.1% ophthalmic suspension of tacrolimus is a
topical preparation of calcineurin inhibitor that was
developed specifically for the treatment of severe al-
lergic conjunctivitis, including VKC and AKC.
Tacrolimus inhibits calcineurin activity, leading to
marked suppression of the production of various cy-
tokines by activated T cells (including IL-2, IL-4, IL-5,
and interferon-gamma).17 On account of its potent im-
munosuppressive activity, tacrolimus was considered
to show promise for application to intractable allergic
eye diseases. After studies conducted in Japan proved
the usefulness of 0.1% tacrolimus ophthalmic suspen-
sion,12 it was released in 2008.
On the other hand, it is known that adverse drug
reactions to tacrolimus, such as renal dysfunction,
tend to occur with systemic use when a whole blood
concentration of about 10 ngmL (trough level) per-
sists for a long time.13 Furthermore, a recent review
focused on the potential risk of T cell lymphoma in
patients using tacrolimus ointment.15 The age- and
sex-adjusted hazard ratio for T cell lymphoma was
5.44 (95% Cl: 2.51-11.79; P < 0.001) for patients ex-
posed to tacrolimus versus those not exposed. How-
ever, no data on the blood levels of tacrolimus were
reported for the patients who developed T cell lym-
phoma. Because systemic immunosuppression is as-
sociated with an increased risk of lymphoma, there is
a theoretical possibility that tacrolimus ointment
could increase the risk of lymphoma. However, there
is no evidence of a causal link between cancer and
Ebihara N et al.
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Table　3　Adverse drug reactions and laboratory abnormalities
Number (%) of patients or events
Not detected†
(N = 32)
Detected†
(N = 20)
Adverse drug reactions 10 (31.25) 6 (30.00)
Warmness in eye  7 (21.88) 1 (5.00)
Eye irritation  1 (3.13) 3 (15.00)
Burning sensation in eye  1 (3.13) 1 (5.00)
Dysgeusia  1 (3.13) 0
Acute bronchitis  0 1 (5.00)
Throat irritation  0 1 (5.00)
Overall events 10 (31.25) 7 (35.00)
Clinical laboratory abnormalities  6 (18.75) 2 (10.00)
Neutrophil count decreased  0 1 (5.00)
White blood cell count increased  0 1 (5.00)
Eosinophil count decreased  0 1 (5.00)
Blood sugar decreased  0 1 (5.00)
Haemoglobin decreased  1 (3.13) 0
Haematocrit decreased  1 (3.13) 0
White blood cell count increased  2 (6.25) 1 (5.00)
Atypical lymphocytes  0 1 (5.00)
Aspartate aminotransferase increased  1 (3.13) 0
Alanine aminotransferase increased  1 (3.13) 1 (5.00)
Blood lactate dehydrogenase increased  2 (6.25) 0
Blood urea increased  1 (3.13) 0
Amylase increased  1 (3.13) 0
Overall events 10 (31.25) 7 (35.00)
†Blood level of tacrolimus during the study period.
Table　4　Visual acuity and intraocular pressure (IOP)
Baseline
(N)
Week 12
(N) P value*
Best visual acuity (mean ± SD) 0.99 ± 0.45
(52)
1.20 ± 0.37
(52)
P < 0.001
IOP (mmHg) (mean ± SD)
 Not-combined with steroids 12.6 ± 2.86
(26)
12.5 ± 2.45
(26)
P = 0.469
Combined with steroids temporarily and/or throughout study period 14.2 ± 2.34
(25)
14.6 ± 2.65
(24)
P = 0.830
*P value were calculated with the use of the Wilcoxon signed rank test compared with baseline value.
tacrolimus.18-25 Many pharmacokinetic studies have
shown that systemic exposure to tacrolimus is low in
patients using the ointment, with blood concentra-
tions being below the limit of quantification (0.5 ng
mL) in the majority of patients.26-31 In this study, to
evaluate the safety of 0.1% tacrolimus ophthalmic sus-
pension, we investigated the blood level of tacrolimus
in patients using the suspension.
Blood levels of tacrolimus were monitored in all 52
patients during the study period. About 75% of the pa-
tients without concomitant using tacrolimus ointment
had blood levels below the detection limit of the as-
say (0.5 ngmL). On the other hand, 71% (week 4)
and 57% (week 12) of patients with concomitant using
of tacrolimus ointment had blood levels above the de-
tection limit of the assay (0.5 ngml). However, the
maximum blood concentration was lower than 2 ng
mL, which was less than high risk level (10 ngmL)
at which systemic adverse drug reactions might oc-
cur. Therefore, the theoretical risk of adverse effects
Blood Concentrations of Tacrolimus
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Fig.　1　Changes of the total scores for symptoms and signs during the 12-week study period. 
Error bars represent the standard deviation. The signifi cance of differences was evaluated by 
using the Wilcoxon signed rank test to assess the change of each score in comparison with 
the baseline value. *P < 0.0001.
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due to exposure to tacrolimus is very low because no
evidence of accumulation was observed after re-
peated use of 0.1% tacrolimus ophthalmic suspension
with or without concomitant using of tacrolimus oint-
ment. Despite this finding, especially for patients with
concomitant using of tacrolimus ointment, caution
may be required to monitor the blood level of
tacrolimus.
Among the 52 patients, adverse drug reactions oc-
curred in 16. The most common adverse events asso-
ciated with 0.1% tacrolimus ophthalmic suspension
treatment were transient application-site reactions,
such as warmness, irritation, and a burning sensa-
tion. However, all of the patients could continue treat-
ment with tacrolimus for 12 weeks. These complica-
tions were related to their ocular diseases and de-
creased in frequency over time as allergic conjunctivi-
tis showed improvement. Because tacrolimus modu-
lates the local immune response at the ocular surface,
treatment with 0.1% tacrolimus ophthalmic suspen-
sion could theoretically increase the risk of infec-
tions. However, there was no increase in the inci-
dence of infections among adults or children in the
present study. Despite this finding, especially for pa-
tients with a history of herpes simplex infection, cau-
tion may be required to prevent recurrence during
long-term treatment.32
During this study, when 0.1% tacrolimus ophthal-
mic suspension was used for 12 weeks, giant papillae
and corneal disorders showed marked improvement.
The effect was significant after only 2 weeks of treat-
ment, and both symptoms and objective findings re-
sponded quickly to 0.1% tacrolimus ophthalmic sus-
pension.
In conclusion, we evaluated the safety and efficacy
of 0.1% tacrolimus ophthalmic suspension in patients
with severe allergic conjunctivitis. On the basis of the
blood concentration profile of tacrolimus, systemic
exposure was minimal and transient after topical ap-
plication of the ocular preparation. The safety of 0.1%
tacrolimus ophthalmic suspension and its demon-
strated efficacy make it an important option for the
treatment of severe allergic conjunctivitis.
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